FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

	Check this box if no longer subject to
$\Box$	Section 16. Form 4 or Form 5
$\cup$	obligations may continue. See
	Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					01 .	Section	30(11)	OI LITE	ilivesi	ineni C	ompany Act	01 1940								
Name and Address of Reporting Person*  In the control of the						2. Issuer Name <b>and</b> Ticker or Trading Symbol Aerpio Pharmaceuticals, Inc. [ NONE ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Khuong Chau Quang					1				,		-		X Dire	ctor		X 1	0% Owi	ner		
(Last) (First) (Middle) C/O AERPIO PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 03/15/2017								Offic belo	cer (give title ow)			other (sp elow)	pecify	
9987 CARVER ROAD, SUITE 420					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable						
(Street)					-	,,									Line)  X Form filed by One Reporting Person					
CINCINNATI OH 25242															Form filed by More than One Reporting Person					
(City)	(	State)	(Zip)																	
		Tal	ole I - I	Non-Deriv	<b>/ative</b>	Seci	uritie	s Ac	cquir	ed, Di	isposed o	f, or E	Benefici	ally Own	ed					
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Ye						Execution Date,			3. Transaction Code (Instr. 8)  4. Securities Acquire Disposed Of (D) (Inst 5)				5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				(iiisti. 4)			
Common Stock 03/15				03/15/2	)17						762,995	A	\$5	4,416,446		I		See Footn	notes <sup>(1)(2)</sup>	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversio or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu	Execution Date, if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ate Exer ration D ath/Day/		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		8. Price of Derivative Security (Instr. 5)	9. Num derivat Securit Benefic Owned Follow Report Transa (Instr. 4	ive ties cially ing ed ction(s)	10. Owner Form: Direct or Indi (I) (Inst	ship o (D) C rect (I	11. Nature of Indirect Beneficial Ownership Instr. 4)	
					Code	v	(A)	(D)	Date Exer	cisable	Expiration Date	Title	Amount or Number of Shares							

## **Explanation of Responses:**

1. These shares are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of GP V. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors. By virtue of such relationships, GP V, Advisors and Isaly may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of Advisors.

2. Each of GP V, Advisors, Isaly and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

## Remarks:

/s/Chau Khuong

03/17/2017

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.